An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zepatier

Chemical Nameelbasvir and grazoprevir
Dosage FormTablet (oral; elbasvir mg/grazoprevir mg: 50 mg/100 mg)
Drug ClassAntivirals
SystemDigestive
CompanyMerck & Co.
Approval Year2016

Indication

  • To treat patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zepatier (elbasvir and grazoprevir) Prescribing Information2019Merck Sharp & Dohme Corp.
Document TitleYearSource
Zepatier (grazoprevir and elbasvir) for chronic hepatitis C infection.2017Hayes Inc.
Elbasvir–grazoprevir for treating chronic hepatitis C.2016NICE
Document TitleYearSource
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co‐infection: systematic review and network meta‐analysis.2020Journal of Gastroenterology and Hepatology